R&ME StudyKit
Sign in
BPC-157animalAnimal model2025

Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on "Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185".

Pharmaceuticals (Basel, Switzerland)

confidence

Key findings

This is a reply to a comment on a literature/patent review of BPC 157; no clinical or biological endpoints are reported.

View source on PubMed (PMID 41155566) ↗

Sample size
Not reported
Population
Not applicable (reply to comment)
Dosing
Not reported
Duration
Not reported
Route
Not reported
Blinding
not_reported
Controls
not_reported
Drug class
peptide
Full abstract

We wish to thank the Authors of the comment for their interest in our manuscript [...].

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.